Moderna Inc MRNA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD

After Hours: Last | 7:58 PM EST

130.00

-2.30 (-1.74%)

Volume

117,577

132.30

+1.08 (+0.82%)

Volume

10,612,033

52 week range

19.31 - 189.26

...

Loading . . .

KEY STATS

Open128.70
Day High135.47
Day Low126.69
Prev Close131.22
52 Week High189.26
52 Week High Date02/08/21
52 Week Low19.31
52 Week Low Date03/13/20
Market Cap52.89B
Shares Out399.77M
10 Day Average Volume11.42M
Dividend-
Dividend Yield-
Beta1.5
1 Year % Change381.27

RATIOS/PROFITABILITY

EPS (TTM)-1.94
P/E (TTM)-68.29
Fwd P/E (NTM)8.82
EBITDA (MRQ)-731.893M
ROE (MRQ)-39.99%
Revenue (MRQ)803.40M
Gross Margin (MRQ)70.05%
Net Margin (MRQ)-92.99%
Debt To Equity (MRQ)4.29%

EVENTS

Earnings Date05/05/2021
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest Moderna Inc News

12 Hours Ago

Cramer says it's time to rotate into these forgotten industrials CNBC.com

March 3, 2021

Companies with the worst numbers suddenly have the best stocks, Jim Cramer says CNBC.com

March 3, 2021

Cramer says post-Covid travel boom could be 'sky's the limit,' investors be ready CNBC.com

March 3, 2021

Johnson & Johnson's Covid vaccine rolls out across the U.S., boosting supplies CNBC Video

CNBC.com

March 2, 2021

J&J CEO on Merck vaccine deal: 'Extraordinary times take extraordinary efforts' CNBC.com

Latest MRNA News From Our Partners

9 Hours Ago

Moderna, IBM to partner on improving COVID-19 vaccine management Seeking Alpha

March 3, 2021

Early March Vaccine Thoughts Seeking Alpha

March 2, 2021

Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon Seeking Alpha

March 2, 2021

Moderna to seek Japanese approval for COVID-19 vaccine later this week Seeking Alpha

March 2, 2021

Moderna to seek Japanese approval for COVID-19 vaccine later this week Seeking Alpha

QUOTE FINDER

Market Movers

Profile

Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced...

Noubar Afeyan Ph.D.

Non-Executive Chairman

Stephane Bancel

Chief Executive Officer

Stephen Hoge M.D.

President

David Meline

Chief Financial Officer

Juan Andres

Chief Technology Officer

Lori Henderson J.D.

General Counsel

Address

200 Technology Sq

Cambridge, MA

02139-3578

United States

https://www.modernatx.com/

Moderna Inc MRNA:NASDAQ

KEY STATS

RATIOS/PROFITABILITY

EVENTS

QUOTE FINDER

Related Video

Profile